MK 571
(Synonyms: MK-571钠盐) 目录号 : GC12197
A selective CysLT1 receptor antagonist
Cas No.:115104-28-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
U937 cell line |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reaction Conditions |
IL-6 protein determination: Freshly isolated monocytes were stimulated with medium, LPS (1 ng/ml), MK-571 (10 μM), and the combination of both during 24 h. |
|
Applications |
Costimulating the cells with 10 μM MK-571 and 1 ng/ml LPS enhanced IL-6 secretion（2.0±0.4 fold increase, p＜0.01）than cells only stimulated by LPS. And a 1.6 fold increase in IL-6 mRNA expression was also observed by the combination of LPS and MK-571 compared to the effects of LPS alone. |
| Animal experiment [2]: | |
|
Animal models |
Sensitized male Balb/c mice weighing 20±25 g |
|
Dosage form |
Effect of MK-571on cell infiltration: Animals were treated with an injection of MK-571 in the caudal vein (1, 10, 100 mg/kg ) for 30 min |
|
Applications |
The MK-571 inhibition for eosinophil infiltration in the bronchoalveolar lavage was 46%, 63.9% and 90% at the dose of 1 mg/kg, 10 mg/kg and 100 mg/kg. And MK-571 produced a total inhibition of neutrophil infiltration. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Edo Vellenga, Leonore Tuyt, Bart-Jan Wierenga, Michael Muller & Wim Dokter. Interleukin-6 production by activated human monocytic cells is enhanced by MK-571, a specifc inhibitor of the multi-drug resistance protein-1. Br J Pharmacol, 1999, 127(2): 441-448. [2]. Blain JF, Sirois P. Involvement of LTD(4) in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571. Prostaglandins Leukot Essent Fatty Acids, 2000, 62(6): 361-368. |
|
MK 571 (L-660,711) is a novel potent and selective antagonist of leukotriene D4 receptor with Ki values of 0.22 nM and 2.1 nM in guinea pig and human lung membranes, respectively [1]. MK 571 is also a specific inhibitor of the multidrug resistance protein 1 (MRP1) [2].
Leukotriene D4 (LTD4) is one of the leukotrienes and is released by basophils. LTD4 induces the contraction of smooth muscle and increases vascular permeability. Cysteinyl leukotriene receptor 1 (cysLT1 receptor, LTD4 receptor) is a G protein-coupled receptor activated by LTD4 [3].
MK 571 (L-660,711) is a potent, selective and orally active leukotriene D4 receptor antagonist. MK 571 competitively antagonized contractions of guinea pig trachea and ileum induced by LTD4 (pA2 values, 9.4 and 10.5) and LTE4 (pA2 values, 9.1 and 10.4) , and antagonized contractions of human trachea induced by LTD4 with pA2 value of 8.5 [1].
In anesthetized guinea pigs, MK 571 antagonized bronchoconstriction induced by LTC4, LTD4, and LTE4 [1]. In mice, MK 571 (1, 10, 100 mg/kg) inhibited inflammatory cell infiltration in the bronchoalveolar lavage in a dose-dependent way with maximal inhibition of 90%. MK 571 also inhibited bronchial hyperreactivity and reduced lung microvascular leakage by 22% at 10 mg/kg [3].
References:
[1]. Jones TR, Zamboni R, Belley M, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol, 1989, 67(1): 17-28.
[2]. Vellenga E, Tuyt L, Wierenga BJ, et al. Interleukin-6 production by activated human monocytic cells is enhanced by MK-571, a specific inhibitor of the multi-drug resistance protein-1. Br J Pharmacol, 1999, 127(2): 441-448.
[3]. Blain JF, Sirois P. Involvement of LTD(4) in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571. Prostaglandins Leukot Essent Fatty Acids, 2000, 62(6): 361-368.
| Cas No. | 115104-28-4 | SDF | |
| 别名 | MK-571钠盐 | ||
| 化学名 | (R,E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid | ||
| Canonical SMILES | ClC1=CC=C2C(N=C(C=C2)/C=C/C3=CC([C@@H](SCCC(O)=O)SCCC(N(C)C)=O)=CC=C3)=C1 | ||
| 分子式 | C26H27ClN2O3S2 | 分子量 | 515.09 |
| 溶解度 | <5.15mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9414 mL | 9.707 mL | 19.4141 mL |
| 5 mM | 0.3883 mL | 1.9414 mL | 3.8828 mL |
| 10 mM | 0.1941 mL | 0.9707 mL | 1.9414 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。